1. Gruppo Italiano per lo Studio della Streptochianasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:65-71.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
3. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-1348.
4. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100:1016-1030.
5. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
6. Ohman EM, Califf RM, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781-791.
7. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. Circulation 1995;91:2725-2732.
8. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 1996;94:891-898.
9. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997;95:351-356.
10. Cannon CP, Gibson CM, McCabe CH, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 1998;98:2805-2814.
11. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337: 1118-1123.
12. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-722.
13. Coller BS. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy. Eur Heart J 1995;16(Suppl. L):11-15.
14. Jang I-K, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation 1989;79:920-928.
15. Walsh PN, Schmaier AH. Platelet-coagulant protein interactions. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. J.B. Lippincott Company, Philadelphia, 1994, pp. 629-651.
17. Weitz JI, Huboda M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
18. Loscalzo J, Melnick B, Handin R. The interaction of platelet factor 4 and glycosaminoglycans. Arch Biochem Biophys 1985;240:446-455.
19. Hirsh J, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1992;102:337S-351S.
20. Miller ML. Heparin-induced thrombocytopenia. Cleve Clin J Med 1989;56:483-490.
21. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-68.
22. Fitzgerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-150.
23. Kerins DM, Roy L, FitzGerald GA, Fitzgerald DJ. Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation 1989;80:1718-1725.
24. Eisenberg PR, Sobel BE, Jaffe AS. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992;19:1065-1069.
25. Merlini PA, Bauer KA, Oltrona L, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995;25: 203-209.
26. Genser N, Mair J, Maier J, Dienstl F, Puschendorf B, Lechleitner P. Thrombin generation during infusion of tissue-type plasminogen activator. Lancet 1993;341:1038.
27. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol 1987;10:527-529.
28. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988;72: 616-620.
29. Rapold HJ, de Bono D, Arnold AE, et al. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group. Circulation 1992;85:928-934.
30. Galvani M, Abendschein DR, Ferrini D, Ottani F, Rusticali F, Eisenberg PR. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J Am Coll Cardiol 1994;24:1445-1452.
31. Seitz R, Blanke H, Prätorius G, Strauer BE, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemost 1988;59:541-542.
32. Bloom AL. The release of thrombin from fibrin by fibrinolysis. Br J Haematol 1962;82:129-133.
33. Lee CD, Mann KG. Activation/inactivation of human factor V by plasmin. Blood 1989;73:185-190.
35. Fuster V Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (Part 2). N Engl J Med 1992;326:310-318.
36. Schafer AI. The platelet life cycle: normal function and qualitative disorders. In: Handin RI, Lux SE, Stossel TP, eds. Blood: Principles and Practice of Hematology. J.B. Lippincott Company, Philadelphia, 1995, pp. 1095-1126.
37. Colman RW, Cook JJ, Niewiarowski S. Mechanisms of platelet aggregation. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. J.B. Lippincott Company, Philadelphia, 1994, pp. 508-523.
38. Hawinger J, Brass LF, Salzman EW. Signal transduction and intracellular regulatory processes in platelets. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. J.B. Lippincott Company, Philadelphia, 1994, pp. 603-628.
39. Handin RI. Platelet membrane proteins and their disorders. In: Handin RI, Lux SE, Stossel TP, eds. Blood: Principles and Practice of Hematology. J.B. Lippincott Company, Philadelphia, 1995, pp. 1049-1067.
40. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
41. Schafer AI. Antiplatelet therapy. Am J Med 1995;101:199-209.
42. Verstraete M. New developments in antiplatelet and antithrombotic therapy. Eur Heart J 1995;16: 16-23.
43. Frishman WH, Burns B, Atac B, Alturk N, Altajar B, Lerrick K. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor. Am Heart J 1995;130:877-892.
44. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-1294.
45. Willard JE, Lange RA, Hillis LD. The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327:175-181.
46. Campbell WB. Lipid-derived autacoids: eicosanoids and platelet-activating factor. In: Gilman AG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacologic Basis of Therapeutics. Perg-amon Press, New York, 1990, pp. 600-617.
47. Jaffe EA, Weksler BB. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. J Clin Invest 1979;63:532-535.
48. Hanson SR, Harker LA, Bjornsson TD. Effects of platelet-modifying drugs on arterial thromboem-bolism in baboons: Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest 1985;75:1591-1599.
49. Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 1987;79: 1788-1797.
50. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs: the relationship between dose, effectiveness, and side effects. Chest 1992;102 (Suppl. 4):327S-336S.
51. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982;69:1366-1372.
52. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983;308:800-805.
53. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
54. Baigent C, Collins R. ISIS-2: 4-year mortality follow-up of 17,187 patients after fibrinolytic and antiplatelet therapy in suspected acute myocardial infarction [abstract]. Circulation 1993;88(Suppl. I): I-291.
55. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-1672.
56. Defreyn G, Gachet C, Savi P, Driot F, Cazenave JP, Maffrand JP. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost 1991;65:186-190.
57. Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM. Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb 1993;13:393-397.
58. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombosthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985;75:328-338.
59. Defreyn G, Bernat A, Delebassee D, Maffrand JP. Pharmacology of ticlopidine: a review. Semin Thromb Hemost 1989;15:159-166.
60. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313-317.
61. Seyfarth HJ, Koksch M, Roethig G, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J 2002;143:118-123.
62. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;2:1215-1220.
63. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
64. Schömig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
65. Schömig A, Neumann F-J, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997;29:28-34.
66. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665-1671.
67. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000;101: 590-593.
68. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
69. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intra-coronary stent implantation in a broad patient population. Circulation 2001;104:539-543.
70. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339.
71. The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
72. Hacker LA, Mann KG. Thrombosis and fibrinolysis. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. WB Saunders, Philadelphia, 1992, pp. 1-16.
73. Sabatine MS, Jang I-K. The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med 2000;109:224-237.
74. Coller BS. A new murine monoclonal antibody reports an activation dependent change in the conformation and/or microenvironment of the glycoprotein IIb/IIIa complex. J Clin Invest 1985;76: 101-108.
75. Scarborough RM, Naughton MA, Teng W, et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993;268:1066-1073.
76. Goa KL, Noble S. Eptifibatide. Drugs 1999;57:439-462.
77. Hartman GD, Egbertson MS, Halczenko W, et al. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J Med Chem 1992;35:4640-4642.
78. McClellan KJ, Goa KL. Tirofiban. Drugs 1998;56:1067-1080.
79. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813.
80. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytope-nia in a population undergoing high-risk percutaneous coronary revascularization. J Am Coll Cardiol 1998;32:311-319.
81. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104:870-875.
82. Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98: 731-741.
83. Neumann F-J, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abcix-imab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-921.
84. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
85. Stone GW. Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.
86. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis after Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993;22:381-389.
87. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 1999;99: 2720-2732.
88. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000; 101: 2788-2794.
89. Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J 2000;21:1944-1953.
90. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Mycardial Infarction (TIMI) 23 Trial. Circulation 2002;105:1642-1649.
91. The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-1914.
92. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613.
93. Ohman EM, Kleiman NS, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846-854.
94. Simoons ML. Streptokinase with platelet glycoprotein IIb/IIIa blockade (eptifibatide): an angio-graphic study, Thrombolysis and Interventional Therapy in Acute Myocardial Infarction, Orlando, November 8, 1997.
95. Brener SJ, Vrobel TR, Lopez JF, et al. INTRO AMI: marked enhancement of arterial patency with eptifibatide and low-dose t-PA in acute myocardial infarction. Circulation 1999;100(Suppl.):I-649.
96. Giugliano RP, Roe MT, Zeymer U, et al. Restoration of epicardial and myocardial perfusion in acute ST-elevation myocardial infarction with combination eptifibatide + reduced-dose tenecteplase: dose-finding results from the INTEGRITI trial. Circulation 2001;104(Suppl. II):II-538.
97. Brochier ML, for the Flurbiprofen French Trial. Evaluation of flurbiprofen for prevention of reinfarc-tion and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. Eur Heart J 1993;14:951-957.
98. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
99. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959.
100. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-2288.
101. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.
102. Anturane Reinfarction Italian Study. Sulfinpyrazone in post-myocardial infarction. Lancet 1982;1: 237-42.
103. FitzGerald GA. Dipyridamole. N Engl J Med 1987;316:1247-1257.
104. Gent AE, Brook CGD, Foley TH, Miller TN. Dipyridamole: a controlled trial of its effect in acute myocardial infarction. BMJ 1968;4:366-368.
105. De Clerck F, Bettens J, de Chaffoy de Courcelles D, Freyne E, Janssen PAJ. R 68070: thromboxane synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule—I. Biochemical profile in vitro. Thromb Haemost 1989;61:35-42.
106. De Clerck F, Bettens J, Van de Water A, Vercammen E, Janssen PAJ. R 68070: thromboxane synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one mol-ecule—II. Pharmacologic effects in vivo and ex vivo. Thromb Haemost 1989;61:43-49.
107. The RAPT Investigators. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction: the Ridogrel versus Aspirin Patency Trial (RAPT). Circulation 1994;89:588-595.
108. Schror K. Antiplatelet drugs: a comparative review. Drugs 1995;50:7-28.
109. Topol EJ, Ellis SG, Califf RM, et al. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J Am Coll Cardiol 1989;14:877-884.
110. Takamatsu J, Horne MD, Gralnick HR. Identification of the thrombin receptor on human platelets by chemical crosslinking. J Clin Invest 1986;77:362-369.
111. Coughlin SR, Vu TKH, Wheaton TI. Characterization of a functional thrombin receptor: issues and opportunities. J Clin Invest 1992;89:351-355.
112. Van Willigen G, Akkerman JW. Regulation of glycoprotein IIb/IIIa exposure on platelets stimulated with alpha-thrombin. Blood 1992;79:82-90.
113. Lumsden AB, Kelly AB, Schneider PA, et al. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. Blood 1993;81:1762-1770.
114. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1995;75:12B-17B.
115. Miller JL, Thiam-Cisse M, Drouet LO. Reduction in thrombus formation by PG-1 (Fab'), an anti-guinea pig platelet glycoprotein Ib monoclonal antibody. Arteriosclerosis Thromb 1991;11:1231-1236.
116. Bellinger DA, Nichols TC, Read MS, et al. Prevention of occlusive coronary thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc Natl Acad Sci USA 1987;84:8100-8104.
117. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994;90: 1522-1536.
118. Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 1993;69:1-58.
119. Sonder SA, Fenton JW. Proflavin binding within the fibrinopeptide groove adjacent to the catalytic site of human alpha-thrombin. Biochemistry 1984;23:1818-1823.
120. Rihal CS, Flather M, Hirsh J, Yusuf S. Advances in antithrombotic drug therapy for coronary artery disease. Eur Heart J 1995;16:10-21.
121. Ali MN, Villarreal-Levy G, Schafer AI. The role of thrombin and thrombin inhibitors in coronary angioplasty. Chest 1995;108:1409-1419.
122. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
123. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-813.
124. Broze GJJ. Tissue factor pathway inhibitor. Thromb Haemost 1995;74:90-93.
125. Huang ZF, Wun T-C, Broze GJJ. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 1993;268:26950-26955.
126. Johnson EA, Mulloy B. The molecular weight range of commercial heparin preparations. Carbohydr Res 1976;51:119-127.
127. Anderson L, Barrowcliffe TW, Holmer E, Johnson EA, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X: effect of heparin neutralization in plasma. Thromb Res 1979;15:531-541.
128. Andersson LO, Barrowcliffe TW, Holmer E. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979;115:531.
129. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocy-topenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-88.
130. Aster R. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;335:1374-1376.
131. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-145.
132. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91: 1929-1935.
133. Smith AJC, Holt RE, Fitzpatrick K, et al. Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. Am Heart J 1996;131:434-439.
134. Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996;313:652-659.
135. The SCATI (Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nee'Infarto) Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 1989;2:182-186.
136. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-1417.
137. ISIS (International Studies of Infarct Survival) Pilot Study Investigators. Randomized factorial trial of high-dose intravenous streptokinase, or oral aspirin and of intravenous heparin in acute myocardial infarction. Eur Heart J 1987;8:634-642.
138. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
139. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-75.
140. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339: 753-770.
141. de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992;67:122-128.
142. Col J, Decoster O, Hanique G, et al. Infusion of heparin conjunct to streptokinase accelerates reperfusion of acute myocardial infarction. Results of a double blind randomized study (OSIRIS). Circulation 1992;86(Suppl. I):I-259.
143. O'Connor CM, Meese R, Carney R, et al. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: The Duke University Clinical Cardiology Study (DUCCS) 1. J Am Coll Cardiol 1994;23: 11-18.
144. Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue-plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323: 1433-1437.
145. Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol 1996;77: 551-556.
146. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
147. Neuhaus K-L, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14: 1566-1569.
148. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90:1624-1630.
149. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631-1637.
150. Neuhaus K-L, von Essen R, Tebbe U, et al. Safety observation from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation 1994;90: 1638-1642.
151. Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996;93: 870-878.
152. Cannon CP, Braunwald E. Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol 1995;25(Suppl.):30S-37S.
153. Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 1989;15: 269-282.
154. Krstenansky JL, Mao SJT. Antithrombin properties of the C-terminus of hirudin using synthetic unsul-fated N-a-acetyl-hirudin. FEBS Lett 1987;211:10-16.
155. Stone SR, Maraganore JM. Hirudin interactions with thrombin. In: Berliner LJ, ed. Thrombin: Structure and Function. Plenum Press, New York, 1992, pp. 219-256.
156. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-386.
157. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23: 993-1003.
158. Lee LV Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 1995;75:7-13.
159. Antman EM, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibitors in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-922.
160. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782.
161. Neuhaus K-L, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 1999;34:966-973.
162. Chesebro JH. Direct thrombin inhibition superior to heparin during and after thrombolysis: dose, duration, and drug. Circulation 1997;96:2118-2120.
163. Serruys PW, Herrman J-P, Simon R, et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 1995;333:757-763.
164. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333:764-769.
165. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
166. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin b3 blockade with percutaneous intervention. JAMA 1997;278: 479-484.
167. Zoldhelyi P, Jassens S, Lefevre G, Collen D, Van de Werf F, for the GUSTO-2A Investigators. Effects of heparin and hirudin (CGP 39393) on thrombin generation during thrombolysis for acute myocardial infarction. Circulation 1995;92(Suppl. I):I-740.
168. Rao AK, Sun L, Chesebro JH, et al. Distinct effects of recombinant desulfatohirudin CGP 39,393 and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina: a multicenter trial. Thromb Haemost 1995;73:1306.
169. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095-7101.
170. Lidón R-M, Théroux P, Lespérance J, et al. A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 1994;89:1567-1572.
171. Théroux P, Pérez-Villa F, Waters D, Lespérance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995;91: 2132-2139.
172. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-2161.
173. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001;358:1855-1863.
174. Okamoto S, Hijikata A, Kikumoto R, et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981;101:440-446.
175. Kikumoto R, Tamao Y, Tezuka T, et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-arginyl]-2-piperidinecarboxylic acid. Biochemistry 1984;23:85-90.
176. Fitzgerald D, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coron Artery Dis 1996;7:455-458.
177. Lunven C, Gauffeny C, Lecoffre C, O'Brien DP, Roome NO, Berry CN. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996;75:154-160.
178. Jang IK, Brown DFM, Giugliano RP, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial Infarction with Novastan and TPA (MINT) study. J Am Coll Cardiol 1999;33:1879-1885.
179. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79:1-17.
180. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
181. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994;24:105-117.
182. Weitz J. New anticoagulant strategies. Current status and future potential. Drugs 1994;48:485-497.
183. Melandri G, Semprini F, Cervi V, et al. Comparison of efficacy of low molecular weight heparin (par-naparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol 1993;72:450-454.
184. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1335.
185. Antman EM. The search for replacements for unfractionated heparin. Circulation 2001;103:2310-2314.
186. Wallentin L. ASSENT Plus, 73th Scientific Sessions of the American Heart Association, New Orleans, LA, November 12-15, 2000.
187. Alonso A. AMI-SK, 50th Annual Scientific Sessions of the American College of Cardiology, Orlando, FL, March 2001, 2001.
188. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001;104:648-652.
189. Young JJ, Kereiakes DJ, Grines CL, for the National Investigators Collaborating on Enoxaparin. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J Invasive Cardiol 2000;12 (Suppl. E):E14-E18.
190. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide" (SR 90107/ORG 31540) and standard heparin. Circ Res 1996;79:590-600.
191. Turpie AGG, Gallus AS, Hoek JA, for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001;344: 619-625.
192. Eriksson BI, Bauer KA, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous throm-boembolism after hip-fracture surgery. N Engl J Med 2001;345:1298-1304.
193. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG, the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-1310.
194. Coussement PK, Bassand JP, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study. Eur Heart J 2001;22:1716-1724.
195. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide is a novel inhibitor of blood coagulation factor Xa. Science 1990;248:593-596.
196. Neeper MP, Waxman L, Smith DE, et al. Characterization of recombinant tick anticoagulant peptide: a highly selective inhibitor of blood coagulation factor Xa. J Biol Chem 1990;265:17746-17752.
197. Vlasuk GP. Structural and functional characterization of tick anticoagulant peptide (TAP): a potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost 1993;70:212-216.
198. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide: comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992;85:805-815.
199. Lynch JJ Jr, Sitko GR, Mellott MJ, et al. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc Res 1994;28:78-85.
200. Nicolini FA, Lee P, Malycky JL, et al. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis 1996;7:39-48.
201. Broze GJJ, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor Vll-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988;71:335-343.
202. Girard TJ, Warren LA, Novotny WF, et al. Functional significance of the Kunitz-type inhibitor domains of lipoprotein-associated coagulation inhibitor. Nature 1989;338:518-520.
203. Lindahl AK. Tissue factor pathway inhibitor: from unknown coagulation inhibitor to major antithrombotic principle. Cardiovasc Res 1997;33:286-291.
204. Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990;29:7539-7546.
205. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue-factor dependent blood coagulation. Thromb Haemost 1991;66:6-15.
206. Haskel EJ, Torr SR, Day KC, et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991;84:821-827.
207. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995;92:944-949.
208. Kaiser B, Fareed J. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis. Thromb Haemost 1996;76:615-620.
209. Lefkovits J, Nicolini FA, Malycky JL, Rao S, Hart C, Topol EJ. Selective inhibition of factor Xa is more effective than tissue factor-factor VIIa complex blockade at facilitating TPA-induced thrombol-ysis in the canine model. Circulation 1995;92(Suppl. I):I-740.
Was this article helpful?